Fosamax and Osteonecrosis of the Jaw: Understanding the Causal Link and Risk Factors

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Targeted Risk Communication

The legacy of general health and science information has long served as a foundation for public understanding of medical risks and therapeutic benefits. Within this broad context, the dissemination of knowledge regarding pharmaceutical interventions has historically emphasized efficacy and safety profiles, often framed within population-level guidelines. This heritage naturally includes discussions of bone health management, where bisphosphonate therapies have been positioned as standard interventions for conditions such as osteoporosis. As the informational landscape evolved, attention gradually shifted from generalized health promotion to more nuanced considerations of adverse outcomes associated with specific drug exposures. This pivot reflects a maturation in how health information is contextualized, moving from broad educational messaging toward targeted risk communication. Within this trajectory, the focus on Fosamax exposure and its potential association with osteonecrosis of the jaw (ONJ) emerges as a logical extension. The transition from general health science to occupational exposure concern is marked by an increasing emphasis on identifying and characterizing specific risk factors that may influence individual susceptibility. This shift does not rely on mechanistic claims but rather acknowledges the need for precise, context-aware information that bridges population-level data with individual exposure scenarios. The resulting discourse now incorporates considerations of duration, dosage, and patient-specific variables, thereby refining the legacy of general health information into a more specialized framework for risk assessment.

Bridging General Health Science to Fosamax-Specific Risk

Building on the foundation of general health information, the medical literature provides a detailed examination of Fosamax (alendronate) and its association with osteonecrosis of the jaw. Fosamax is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its pharmacological action involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a recognized adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). This condition is characterized by exposed, non-healing bone in the maxillofacial region, often associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation involves pain, swelling, and exposed bone, possibly with purulent discharge or fistula formation. Diagnosis is based on clinical examination and imaging, with a history of bisphosphonate use being a key consideration. Multiscale characterization of jawbone tissue has provided comprehensive information to better understand jawbone-specific responses to complications such as bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Mechanistic Pathways and Risk Factors for Fosamax-Associated ONJ

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated but are believed to involve the drug's potent inhibition of osteoclast activity. Bisphosphonates accumulate in bone, particularly in areas of high turnover such as the jaw, and suppress bone remodeling. This suppression can impair the ability of the jawbone to repair microdamage and respond to local infections or trauma, such as tooth extraction. Additionally, bisphosphonates may have anti-angiogenic effects, reducing blood supply to the jawbone and contributing to necrosis. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under Warnings and Precautions, noting that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and outlines known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the optimal duration of Fosamax use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Evidence of Causation: Temporal Relationship and Dose-Response Data

Causation-related considerations for affected patients involve assessing the temporal relationship between Fosamax exposure and the development of ONJ. The time to onset of symptoms after starting the drug can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms were similar in the Fosamax and placebo groups, suggesting that ONJ is a rare event (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A cohort study among female patients treated for osteoporosis in the United Kingdom found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use, though absolute risks remained low (approximately 0.05% after 5 years) and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This data supports a dose-response relationship, with longer exposure increasing risk. Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The timeline between exposure and documented harm can vary widely. ONJ may develop within months of starting Fosamax or after years of use. The condition is often triggered by dental procedures, but spontaneous cases occur. The risk appears to increase with cumulative exposure, as evidenced by the higher risk after longer treatment durations (https://pubmed.ncbi.nlm.nih.gov/39400702/). Discontinuation of bisphosphonate treatment may reduce the risk for ONJ, particularly before invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). In summary, Fosamax is associated with a rare but serious risk of osteonecrosis of the jaw. The condition is linked to the drug's antiresorptive effects, with risk factors including dental procedures, cancer, and concomitant therapies. Warnings in the prescribing information address this risk, and the evidence supports a causal relationship, particularly with longer exposure. Patients and clinicians should weigh the benefits of fracture prevention against the low absolute risk of ONJ, especially when considering long-term therapy.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how does it work?

Fosamax (alendronate) is a bisphosphonate medication approved for treating and preventing osteoporosis, increasing bone mass in men with osteoporosis, treating glucocorticoid-induced osteoporosis, and treating Paget's disease of bone. It works by inhibiting bone resorption, which increases bone mass and reduces fracture risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What is osteonecrosis of the jaw (ONJ) and how is it linked to Fosamax?

Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the jaw, often associated with tooth extraction or local infection. Fosamax, like other bisphosphonates, can cause ONJ by suppressing bone remodeling and reducing blood supply to the jawbone. Risk factors include invasive dental procedures, cancer, and long-term bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Known risk factors include invasive dental procedures (tooth extraction, implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures). The risk increases with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How strong is the evidence linking Fosamax to ONJ?

Evidence supports a causal relationship, particularly with longer exposure. A UK cohort study found ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use, though absolute risks remain low (approximately 0.05% after 5 years). Most patients improve after stopping the drug, but recurrence can occur upon rechallenge (https://pubmed.ncbi.nlm.nih.gov/39400702/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.